Research published in Journal of Affective Disorders

At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial.

Journal of Affective Disorders July 1, 2022 Thomas D Hull, Matteo Malgaroli, Adam Gazzaley et al. 59 citations

BACKGROUND At-home Ketamine-assisted therapy (KAT) with psychosocial support and remote monitoring through telehealth platforms addresses access barriers, including the COVID-19 pandemic. Large-scale evaluation of this approach is needed for questions regarding safety and effectiveness for depression and anxiety. METHODS In this prospective study, a large outpatient sample received KAT over...

DOI: 10.1016/j.jad.2022.07.004 Full text

Esketamine alleviates postoperative depression-like behavior through anti-inflammatory actions in mouse prefrontal cortex.

Journal of Affective Disorders April 1, 2022 Tian-Yuan Wang, H. Weng, Hong-Jin Zhou et al.

The rising incidence of Postoperative depression (POD) in recent years has placed a heavy burden on patients' physical and mental health. At this point in time, however, POD pathogenesis remains poorly understood and novel therapeutic strategies are being sought. The present study aimed to clarify esketamine's protective effects and possible mechanisms of action in POD. To this avail, we used...

DOI: 10.1016/j.jad.2022.03.072

Nightmares mediate the association between traumatic event exposure and suicidal ideation in frontline medical workers exposed to COVID-19

Journal of Affective Disorders February 1, 2022 Jianyu Que, Le Shi, Wei Yan et al.

Background Trauma experience increases the risk of suicidal ideation, but little is known about potentially psychological mechanisms underlying this relationship. This study aims to examine the relationship between coronavirus disease 2019 (COVID-19)-related traumatic event (CTE) exposure and suicidal ideation among hospital workers, and identify mediating roles of sleep disturbances in this...

DOI: 10.1016/j.jad.2022.02.033 Full text

The Effectiveness of Repeated Intravenous Ketamine on Subjective and Objective Psychosocial Function in Patients with Treatment-Resistant Depression and Suicidal Ideation.

Journal of Affective Disorders February 1, 2022 Yanling Zhou, Chengyu Wang, Xiaofeng Lan et al.

BACKGROUND Ketamine has rapid and robust antidepressant effects in adults with treatment-resistant depression (TRD), while its effects on functional outcomes have not been sufficiently evaluated. The aim was to evaluate the efficacy of ketamine treatment on both subjective and objective functioning, and to explore whether improvements in depressive symptom and cognition mediated changes in...

DOI: 10.1016/j.jad.2022.02.032

A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings.

Journal of Affective Disorders 2022 L. Mcinnes, Jimmy J Qian, Rishab Gargeya et al. 60 citations

BACKGROUND Outcomes of ketamine intravenous therapy (KIT) for depression in real-world care settings have been minimally evaluated. We set out to quantify treatment response to KIT in a large sample of patients from community-based practices. METHODS We retrospectively analyzed 9016 depression patients who received KIT between 2016 and 2020 at one of 178 community practices across the United...

DOI: 10.1016/j.jad.2021.12.097 Full text

mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression.

Journal of Affective Disorders 2022 Lynnette A. Averill, Christopher L. Averill, Ralitza Gueorguieva et al.

Suicide is a public health crisis with limited treatment options. Ketamine has demonstrated rapid and robust improvements in suicidal ideation (SI). The parent study for the secondary pilot analyses presented here was a double-blind, cross-over trial that found pretreatment with the mechanistic target of rapamycin complex 1 (mTORC1) prolonged the antidepressant effects of ketamine. Here we...

DOI: 10.1016/j.jad.2022.01.104

Ketamine vs Midazolam: Mood Improvement Reduces Suicidal Ideation in Depression

Journal of Affective Disorders December 1, 2021 Annabella Hochschild, John G Keilp, Sean P Madden et al.

Objective: Studies demonstrate rapid antidepressant and anti-suicidal ideation effects of subanesthetic ketamine. The specific subcomponents of depression that are most closely tied to reduction of suicidal ideation with ketamine treatment are less explored. Methods: Exploratory, post hoc analysis of data from a randomized clinical trial of ketamine vs midazolam in patients with major...

DOI: 10.1016/j.jad.2021.12.055 Full text

Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression.

Journal of Affective Disorders December 1, 2021 Wei Zheng, Lingna Gu, Chen-Hui Sun et al.

OBJECTIVES Anhedonia is a common, persistent, and disabling phenomenon in patients with major depressive disorder (MDD) and bipolar depression (BD). This study was conducted to investigate the comparative effectiveness of repeated ketamine infusions in treating anhedonia in Chinese individuals suffering from MDD and BD. METHODS Ninety-seven individuals suffering from MDD (n=77) or BD (n=20)...

DOI: 10.1016/j.jad.2021.12.105

Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis.

Journal of Affective Disorders September 17, 2021 Nannan Li, Yi-Ru Hu, Wang-ni Chen et al.

BACKGROUND Previous studies have shown that psilocybin has antidepressant effects. In the current study, we aim to explore the dose effects of psilocybin on primary (major depression patients) and secondary depression (depressed cancer patients). METHODS Published studies concerning psilocybin for depression were retrieved. In accordance with PRISMA guidelines, 6 databases (PubMed, Embase, Web...

DOI: 10.1016/j.jad.2021.09.041

Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment.

Journal of Affective Disorders March 1, 2021 Roger S McIntyre, Nelson B Rodrigues, Orly Lipsitz et al. 10 citations

BACKGROUND Depression severity and efficacy measurement scales employed for rapid-acting treatments (e.g., ketamine) were initially validated in adults receiving conventional monoamine-based antidepressants. The emergence of rapid-acting antidepressants in psychiatry provides the impetus for outcome measures that have been validated as sensitive to change with rapid-acting treatments. Herein,...

DOI: 10.1016/j.jad.2021.03.053

Not all types of meditation are the same: Mediators of change in mindfulness and compassion meditation interventions.

Journal of Affective Disorders February 2, 2021 Pablo Roca, Carmelo Vázquez, Gustavo Díez et al.

BACKGROUND The general aim of the study was to examine the relative effectiveness and mediators of change in standardized mindfulness and compassion interventions. METHODS A sample of 431 participants enrolled in a Mindfulness-Based Stress Reduction program (MBSR = 277) and a Compassion Cultivation Training (CCT = 154). The assessment before and after the program included a set of outcomes and...

DOI: 10.1016/j.jad.2021.01.070

Acute Effects of Cannabis on Symptoms of Obsessive-Compulsive Disorder.

Journal of Affective Disorders January 15, 2021 Dakota Mauzay, Emily M LaFrance, Carrie Cuttler

Little is known about the the acute effects of cannabis on symptoms of OCD in humans. Therefore, this study sought to: 1) examine whether symptoms of OCD are significantly reduced after inhaling cannabis, 2) examine predictors (gender, dose, cannabis constituents, time) of these symptom changes and 3) explore potential long-term consequences of repeatedly using cannabis to self-medicate for OCD...

DOI: 10.1016/j.jad.2020.09.124 Full text

A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions.

Journal of Affective Disorders December 29, 2020 Nelson B Rodrigues, Roger S McIntyre, Orly Lipsitz et al.

BACKGROUND Dissociation is a treatment-emergent adverse event commonly associated with IV ketamine, often measured using the 23-item Clinician-Administered Dissociative States Scale (CADSS). The objective of this study was to develop a short form version of the CADSS for easier clinical use. METHODS Retrospective data of 260 patients with treatment-resistant depression (TRD) receiving IV...

DOI: 10.1016/j.jad.2020.12.119

A randomized controlled trial of mindfulness-based cognitive therapy vs stress management training for obsessive-compulsive disorder.

Journal of Affective Disorders December 27, 2020 Sonal Mathur, M. Sharma, S. Balachander et al.

BACKGROUND Recently, mindfulness-based therapies have emerged as a treatment modality for OCD, but there is sparse controlled data. We report the efficacy of mindfulness-based cognitive therapy (MBCT) in treating OCD in comparison with stress management training (SMT). METHODS 60 outpatients with DSM-IV-TR OCD attending a specialty OCD clinic were randomly assigned in 1:1 ratio to either MBCT...

DOI: 10.1016/j.jad.2020.12.082

Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant

Journal of Affective Disorders November 14, 2020 Stacie Hudgens, Lysbeth Floden, Michael Blackowicz et al. 77 citations

Patients with major depressive disorder who do not respond to ≥2 different pharmacological treatments within the current depressive episode are considered to have treatment resistant depression (TRD). This analysis determined meaningful change thresholds (MCT) of the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) using anchor-based methods and...

DOI: 10.1016/j.jad.2020.11.066 Anxiety Depression economics Patient health questionnaire Rating scale +4

The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis.

Journal of Affective Disorders November 1, 2020 Roger S McIntyre, Isabelle P. Carvalho, Leanna M.W. Lui et al. 186 citations

BACKGROUND Ketamine is established as a rapid and effective treatment in adults with treatment-resistant depression (TRD). The availability of different formulations and routes of delivery invites the need for evaluating relative effect sizes. METHODS Effect size with respect to depression symptom reduction for each formulation and route of delivery was compared at discrete time-points (i.e.,...

DOI: 10.1016/j.jad.2020.06.050

The efficacy of mindfulness meditation apps in enhancing users' well-being and mental health related outcomes: a meta-analysis of randomized controlled trials.

Journal of Affective Disorders October 7, 2020 Éva Gál, Simona Stefan, I. Cristea

BACKGROUND Mindfulness applications are popular tools for improving well-being, but their effectiveness is unclear. We conducted a meta-analysis of randomized controlled trials (RCTs) that employed a mindfulness meditation app as the main intervention to improve users' well-being and mental-health related outcomes. METHODS A systematic search was conducted in PsycINFO, PubMed, Web of Science,...

DOI: 10.1016/j.jad.2020.09.134

Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis

Journal of Affective Disorders September 23, 2020 Anees Bahji, Gustavo Vazquez, Carlos A. Zarate 404 citations

Background: Ketamine appears to have a therapeutic role in certain mental disorders, most notably depression. However, the comparative performance of different formulations of ketamine is less clear. Objectives: This study aimed to assess the comparative efficacy and tolerability of racemic and esketamine for the treatment of unipolar and bipolar major depression. Design: Systematic review and...

DOI: 10.1016/j.jad.2020.09.071 Full text

A randomised trial comparing a brief online delivery of mindfulness-plus-values versus values only for symptoms of depression: Does baseline severity matter?

Journal of Affective Disorders July 21, 2020 Jessica Kingston, L. Becker, J. Woeginger et al.

BACKGROUND Acceptance/mindfulness-based interventions often focus on (a) developing dispositional mindfulness and (b) pursuing personally meaningful and valued activities. Acceptance/mindfulness-based interventions can reduce depression, but little is known about the combined effects of components or the influence of baseline variables on outcomes. This study tested whether practicing a brief...

DOI: 10.1016/j.jad.2020.07.087 Full text

Role of autobiographical memory in the impact of MBCT on dysfunctional attitudes, depressive symptoms and anxiety in bipolar I patients.

Journal of Affective Disorders July 21, 2020 A. Docteur, C. Mirabel-Sarron, Héline Kaya Lefèvre et al.

BACKGROUND The literature suggests that cognitive reactivity in bipolar patients can increase relapse vulnerability, is enhanced by depressive mood and dysfunctional attitudes, and could be improved with MBCT. Autobiographical memory (AM) could be involved in cognitive reactivity, and improved with MBCT training. This study aims to investigate the effect of MBCT for bipolar patients on...

DOI: 10.1016/j.jad.2020.07.072 Full text

Guanosine potentiates the antidepressant-like effect of subthreshold doses of ketamine: Possible role of pro-synaptogenic signaling pathway.

Journal of Affective Disorders June 1, 2020 A. Camargo, A. P. Dalmagro, A. Zeni et al.

Background Augmentation therapies may be effective strategies to potentiate the ketamine's actions with lower potential for knock-on effects. Thus, this study investigated the ability of combined administration of guanosine plus ketamine to elicit an antidepressant-like effect associated with mTOR pathway modulation. The ability of this combined administration to exert an antidepressant-like...

DOI: 10.1016/j.jad.2020.03.186

The NEO-FFI domain of openness to experience moderates ketamine response in treatment resistant depression.

Journal of Affective Disorders 2020 Roman M Dale, Kelly A. Bryant, Nora Finnegan et al. 17 citations

There are many putative mechanisms by which ketamine has its effect and many unanswered questions about risks and benefits of long-term ketamine therapy. A research imperative is the identification of predictors of response to intravenous ketamine, especially a sustained response to maintenance ketamine. Temperament is an inherited aspect of personality and is a predictive factor for outcome in...

DOI: 10.1016/j.jad.2019.09.010 Full text Ketamine Openness to experience Temperament Treatment resistant depression

Antidepressant and antisuicidal effects of ketamine on the functional connectivity of prefrontal cortex-related circuits in treatment-resistant depression: A double-blind, placebo-controlled, randomized, longitudinal resting fMRI study.

Journal of Affective Disorders December 1, 2019 Mu-Hong Chen, Wei-Chen Lin, Pei-Chi Tu et al.

Increasing evidence suggests that infusion of a subanesthetic dose of ketamine exerts antidepressant and antisuicidal effects in patients with treatment-resistant depression (TRD). In this investigation, we used the resting functional connectivity magnetic resonance imaging (fcMRI) to determine the effects of ketamine on the functional connectivity (FC) of prefrontal cortex (PFC)-related...

DOI: 10.1016/j.jad.2019.08.022 Full text Ketamine Treatment-resistant depression Anterior cingulate cortex Functional connectivity +2

Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.

Journal of Affective Disorders November 14, 2019 Fernanda S. Correia-Melo, Gustavo C. Leal, Flávia Vieira et al. 188 citations

BACKGROUND Ketamine and its enantiomers have recently been highlighted as one of the most effective therapeutic options in refractory depression. However, racemic ketamine and esketamine have not been directly compared. The aim of this study is to assess the efficacy and safety of esketamine compared to ketamine in patients with treatment-resistant depression (TRD). METHODS This is a...

DOI: 10.1016/j.jad.2019.11.086

Classical psychedelics for the treatment of depression and anxiety: A systematic review.

Journal of Affective Disorders November 1, 2019 Silvia Muttoni, Maddalena Ardissino, Christopher John 265 citations

Depression and anxiety are prevalent psychiatric disorders that carry significant morbidity. Pharmacological and psychosocial interventions are used to manage these conditions, but their efficacy is limited. Recent interest into the use of psychedelic-assisted therapy using ayahuasca, psilocybin or lysergic acid diethylamide (LSD) may be a promising alternative for patients unresponsive to...

DOI: 10.1016/j.jad.2019.07.076 Full text Depression Psychedelics

Papers